Does the media refer more to PSTV or SPAI?

In the previous week, Safe Pro Group had 4 more articles in the media than Plus Therapeutics. MarketBeat recorded 8 mentions for Safe Pro Group and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Safe Pro Group's score of 0.75 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Safe Pro Group 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PSTV or LAKE?

In the previous week, Lakeland Industries had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Lakeland Industries and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Lakeland Industries' score of 0.44 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakeland Industries 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PSTV or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Vivani Medical N/A N/A -$26.61M -$0.40 N/A

Does the media refer more to PSTV or VANI?

In the previous week, Vivani Medical had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Vivani Medical and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivani Medical's score of 0.70 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HSDT or PSTV more profitable?

Plus Therapeutics has a net margin of -230.24% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Solana -1,427.15% -67.57% -24.09% Plus Therapeutics -230.24% -198.48% -73.13%

Does the media favor HSDT or PSTV?

In the previous week, Plus Therapeutics had 2 more articles in the media than Solana. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Solana. Solana's average media sentiment score of 1.38 beat Plus Therapeutics' score of 0.97 indicating that Solana is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solana 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OM or PSTV?

In the previous week, Plus Therapeutics had 2 more articles in the media than Outset Medical. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Outset Medical. Plus Therapeutics' average media sentiment score of 0.97 beat Outset Medical's score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Outset Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Plus Therapeutics (PSTV) Competitors

$4.29 +0.09 (+2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 +0.01 (+0.35%)

As of 05:16 PM Eastern

Compare

PSTV vs. SPAI, LAKE, VANI, HSDT, and OM

Should you buy Plus Therapeutics stock or one of its competitors? MarketBeat compares Plus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Plus Therapeutics include Safe Pro Group (SPAI), Lakeland Industries (LAKE), Vivani Medical (VANI), Solana (HSDT), and Outset Medical (OM). These companies are all part of the "medical equipment" industry.

How does Plus Therapeutics compare to Safe Pro Group?

Plus Therapeutics (NASDAQ:PSTV) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Plus Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market.

Plus Therapeutics presently has a consensus target price of $56.40, indicating a potential upside of 1,214.69%. Safe Pro Group has a consensus target price of $10.00, indicating a potential upside of 136.41%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Safe Pro Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Safe Pro Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Safe Pro Group has higher revenue and earnings than Plus Therapeutics. Safe Pro Group is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Safe Pro Group	$610K	144.86	-$14.32M	-$0.71	N/A

3.3% of Plus Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 54.8% of Safe Pro Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Safe Pro Group had 4 more articles in the media than Plus Therapeutics. MarketBeat recorded 8 mentions for Safe Pro Group and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Safe Pro Group's score of 0.75 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Safe Pro Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Plus Therapeutics has a net margin of -230.24% compared to Safe Pro Group's net margin of -800.91%. Safe Pro Group's return on equity of -119.17% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Safe Pro Group	-800.91%	-119.17%	-107.17%

Summary

Safe Pro Group beats Plus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Lakeland Industries?

Plus Therapeutics (NASDAQ:PSTV) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Lakeland Industries had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Lakeland Industries and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Lakeland Industries' score of 0.44 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakeland Industries	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakeland Industries has a net margin of -10.87% compared to Plus Therapeutics' net margin of -230.24%. Lakeland Industries' return on equity of -6.64% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Lakeland Industries	-10.87%	-6.64%	-4.13%

Plus Therapeutics has higher earnings, but lower revenue than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Lakeland Industries	$192.65M	0.56	-$25.31M	-$2.13	N/A

Plus Therapeutics currently has a consensus target price of $56.40, suggesting a potential upside of 1,214.69%. Lakeland Industries has a consensus target price of $16.00, suggesting a potential upside of 46.79%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Plus Therapeutics is more favorable than Lakeland Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 71.7% of Lakeland Industries shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 3.4% of Lakeland Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Plus Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Lakeland Industries has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Summary

Lakeland Industries beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Plus Therapeutics compare to Vivani Medical?

Plus Therapeutics (NASDAQ:PSTV) and Vivani Medical (NASDAQ:VANI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 53.3% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vivani Medical is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

Plus Therapeutics presently has a consensus price target of $56.40, indicating a potential upside of 1,214.69%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 209.92%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Vivani Medical had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Vivani Medical and 4 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivani Medical's score of 0.70 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivani Medical has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Vivani Medical	N/A	-264.04%	-79.85%

Plus Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Summary

Plus Therapeutics beats Vivani Medical on 8 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Solana?

Solana (NASDAQ:HSDT) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Solana has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Plus Therapeutics has lower revenue, but higher earnings than Solana. Plus Therapeutics is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	17.07	-$40.89M	-$109.67	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Solana presently has a consensus target price of $3.50, indicating a potential upside of 98.86%. Plus Therapeutics has a consensus target price of $56.40, indicating a potential upside of 1,214.69%. Given Plus Therapeutics' higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Plus Therapeutics had 2 more articles in the media than Solana. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Solana. Solana's average media sentiment score of 1.38 beat Plus Therapeutics' score of 0.97 indicating that Solana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.6% of Solana shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Plus Therapeutics has a net margin of -230.24% compared to Solana's net margin of -1,427.15%. Solana's return on equity of -67.57% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

Solana beats Plus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Plus Therapeutics compare to Outset Medical?

Outset Medical (NASDAQ:OM) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Plus Therapeutics has lower revenue, but higher earnings than Outset Medical. Plus Therapeutics is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.67	-$81.65M	-$4.16	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

3.3% of Plus Therapeutics shares are held by institutional investors. 2.5% of Outset Medical shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Plus Therapeutics had 2 more articles in the media than Outset Medical. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Outset Medical. Plus Therapeutics' average media sentiment score of 0.97 beat Outset Medical's score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Outset Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Outset Medical has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Outset Medical has a net margin of -63.65% compared to Plus Therapeutics' net margin of -230.24%. Outset Medical's return on equity of -56.13% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.65%	-56.13%	-27.45%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Outset Medical currently has a consensus target price of $10.00, suggesting a potential upside of 130.95%. Plus Therapeutics has a consensus target price of $56.40, suggesting a potential upside of 1,214.69%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Plus Therapeutics beats Outset Medical on 8 of the 14 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.53M	$3.06B	$6.84B	$12.44B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	-1.87	19.67	25.83	24.36
Price / Sales	N/A	345.26	540.60	96.08
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	5.96	4.25	10.98	6.49
Net Income	-$22.39M	$64.45M	$3.57B	$336.61M
7 Day Performance	7.79%	4.16%	3.05%	0.91%
1 Month Performance	-26.29%	1.43%	0.72%	-0.35%
1 Year Performance	-45.54%	34.06%	36.81%	31.28%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	2.669 of 5 stars	$4.29 +2.1%	$56.40 +1,214.7%	-46.7%	$29.53M	N/A	N/A	20
SPAI Safe Pro Group	2.95 of 5 stars	$4.66 -3.5%	$10.00 +114.6%	+53.2%	$100.87M	$610K	N/A	11
LAKE Lakeland Industries	3.6204 of 5 stars	$9.77 -3.1%	$16.00 +63.8%	-18.1%	$99.48M	$192.65M	N/A	2,600	Analyst Downgrade
VANI Vivani Medical	3.431 of 5 stars	$1.13 -1.7%	$3.50 +209.7%	-9.1%	$99.17M	N/A	N/A	20
HSDT Solana	3.8831 of 5 stars	$1.63 +0.6%	$3.50 +114.7%	-83.6%	$94.59M	$6.02M	N/A	30	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. SPAI, LAKE, VANI, HSDT, and OM

How does Plus Therapeutics compare to Safe Pro Group?

Summary

How does Plus Therapeutics compare to Lakeland Industries?

Summary

How does Plus Therapeutics compare to Vivani Medical?

Summary

How does Plus Therapeutics compare to Solana?

Summary

How does Plus Therapeutics compare to Outset Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. SPAI, LAKE, VANI, HSDT, and OM

How does Plus Therapeutics compare to Safe Pro Group?

Which has more volatility & risk, PSTV or SPAI?

Do analysts rate PSTV or SPAI?

Which has better valuation and earnings, PSTV or SPAI?

Do insiders & institutionals believe in PSTV or SPAI?

Does the media refer more to PSTV or SPAI?

Is PSTV or SPAI more profitable?

Summary

How does Plus Therapeutics compare to Lakeland Industries?

Does the media refer more to PSTV or LAKE?

Is PSTV or LAKE more profitable?

Which has preferable valuation & earnings, PSTV or LAKE?

Do analysts recommend PSTV or LAKE?

Do insiders and institutionals have more ownership in PSTV or LAKE?

Which has more risk and volatility, PSTV or LAKE?

Summary

How does Plus Therapeutics compare to Vivani Medical?

Do insiders & institutionals believe in PSTV or VANI?

Which has better earnings & valuation, PSTV or VANI?

Do analysts recommend PSTV or VANI?

Does the media refer more to PSTV or VANI?

Is PSTV or VANI more profitable?

Which has more risk & volatility, PSTV or VANI?

Summary

How does Plus Therapeutics compare to Solana?

Which has more volatility & risk, HSDT or PSTV?

Which has preferable earnings and valuation, HSDT or PSTV?

Do analysts recommend HSDT or PSTV?

Does the media favor HSDT or PSTV?

Do institutionals and insiders have more ownership in HSDT or PSTV?

Is HSDT or PSTV more profitable?

Summary

How does Plus Therapeutics compare to Outset Medical?

Which has better valuation & earnings, OM or PSTV?

Do insiders & institutionals have more ownership in OM or PSTV?

Does the media refer more to OM or PSTV?

Which has more risk & volatility, OM or PSTV?

Is OM or PSTV more profitable?

Do analysts recommend OM or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools